×

Presenter

Ignasi Pau-Charles

Dr. Pau-Charles is currently an EU Medical Affairs Lead for lebrikizumab at Almirall and a practicing dermatologist at Clínica Sagrada Família, Barcelona; MediQsalut, Centre Mèdic Torreblanca, Sant Joan Despi; and Atlàntida Assegurances Mèdiques, Barcelona. He obtained his Doctor of Medicine at Universitat Rovira i Virgili, Tarragona, Spain and completed fellowships at Sahlgrenska Universitetssjukhuset (Goteborg, Sweden), Nippon Medical School (Sendagi Bunkyo-ku, Tokyo, Japan), and Universitat de Barcelona, Spain. He completed his dermatology residency in 2013 and his Research Doctorate in cutaneous T-cell lymphoma in 2015 at Universitat de Barcelona, Spain.



Presentations by Ignasi Pau-Charles
Long-term Safety of Tildrakizumab in Patients with Psoriasis: Incidence of Malignancies Through 3 Years from 2 Phase 3 Trials
Long-term Safety of Tildrakizumab in Patients with Psoriasis: Incidence of Malignancies Through 3 Years from 2 Phase 3 Trials
Kristian Reich, Christopher EM Griffiths, Lars Iversen, Andrea Peserico, Ignasi Pau-Charles


No presentations found for today.